ArticleJournal of hematology & oncology2017
Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients.
Article in Journal of hematology & oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 72 citations in OpenAlex.
- Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis.Bone marrow transplantation · 2018Trial
- Soluble immune checkpoints reflect immune activation and treatment response in high-risk systemic sclerosis patients treated with plasma exchange.Journal of translational autoimmunity · 2026Article
- Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells.Nature communications · 2026Article
- Defining immune reset: achieving sustained remission in autoimmune diseases.Nature reviews. Immunology · 2025Review
- Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression.Frontiers in immunology · 2025Review
- Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis.Frontiers in medicine · 2025Article
- T-cell Recovery After Autologous Hematopoietic Stem Cell Transplantation in Autoimmune Diseases.Advances in experimental medicine and biology · 2025Review
- γδ T cell characterisation in the long term after haematopoietic stem cell transplantation and its impact on CMV control and cGVHD severity.Clinical & translational immunology · 2025Article
- Review
- Patients with systemic sclerosis and low CD4 numbers after autologous stem cell transplantation have a favorable outcome.Arthritis research & therapy · 2024Article
- Regulatory B Cells Contribute to the Clinical Response After Bone Marrow-Derived Mesenchymal Stromal Cell Infusion in Patients With Systemic Sclerosis.Stem cells translational medicine · 2023Article
- Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update.Bioengineering (Basel, Switzerland) · 2023Review
- Review
- Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).Bone marrow transplantation · 2022Review
- Non-Classical HLA Determinants of the Clinical Response after Autologous Stem Cell Transplantation for Systemic Sclerosis.International journal of molecular sciences · 2022Article
- Review
- Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis.Frontiers in immunology · 2022Review
- Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations.Bone marrow transplantation · 2021Review
- Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis.Journal of personalized medicine · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The determinants of clinical responses after autologous hematopoietic stem cell transplantation (aHSCT) in systemic sclerosis (SSc) are still unraveled. We analyzed long-term immune reconstitution (IR) and T cell receptor (TCR) repertoire diversity in 10 SSc patients, with at least 6 years simultaneous clinical and immunological follow-up after aHSCT. Patients were retrospectively classified as long-term responders (A, n = 5) or non-responders (B, n = 5), using modified Rodnan's skin score (mRSS) and forced vital capacity (FVC%). All patients had similar severe SSc before aHSCT. Number of reinjected CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.